WO2002058681A8 - Utilisation d'une rhéine pour la préparation d'un médicament pour le traitement d'un taux élevé d'il-1. - Google Patents

Utilisation d'une rhéine pour la préparation d'un médicament pour le traitement d'un taux élevé d'il-1.

Info

Publication number
WO2002058681A8
WO2002058681A8 PCT/FR2002/000271 FR0200271W WO02058681A8 WO 2002058681 A8 WO2002058681 A8 WO 2002058681A8 FR 0200271 W FR0200271 W FR 0200271W WO 02058681 A8 WO02058681 A8 WO 02058681A8
Authority
WO
WIPO (PCT)
Prior art keywords
rhein
treating
medicine
preparing
high level
Prior art date
Application number
PCT/FR2002/000271
Other languages
English (en)
Other versions
WO2002058681A3 (fr
WO2002058681A2 (fr
Inventor
Suzy Charbit
Francois Schutze
Alain Taccoen
Jean-Pierre Pelletier
Diego Provvedini
Original Assignee
Negma Lerads
Suzy Charbit
Francois Schutze
Alain Taccoen
Jean-Pierre Pelletier
Diego Provvedini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Negma Lerads, Suzy Charbit, Francois Schutze, Alain Taccoen, Jean-Pierre Pelletier, Diego Provvedini filed Critical Negma Lerads
Priority to AU2002231927A priority Critical patent/AU2002231927A1/en
Priority to EP02712018A priority patent/EP1363613A2/fr
Priority to MXPA03006596A priority patent/MXPA03006596A/es
Priority to IL15695702A priority patent/IL156957A0/xx
Priority to CA002434052A priority patent/CA2434052A1/fr
Publication of WO2002058681A2 publication Critical patent/WO2002058681A2/fr
Publication of WO2002058681A3 publication Critical patent/WO2002058681A3/fr
Publication of WO2002058681A8 publication Critical patent/WO2002058681A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de la rhéine et de dérivés de rhéine en thérapeutique.La rhéine et des dérivés de rhéine sont utilisés en thérapeutique humaine ou vétérinaire pour le traitement de patients souffrant de maladies inflammatoires et auto-immunes dans lesquelles les cytokines inflammatoires (IL-1 et TNF) sont présentes ô des teneurs anormalement élevées.
PCT/FR2002/000271 2001-01-23 2002-01-23 Utilisation d'une rhéine pour la préparation d'un médicament pour le traitement d'un taux élevé d'il-1. WO2002058681A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002231927A AU2002231927A1 (en) 2001-01-23 2002-01-23 Use of rhein for preparing a medicine for treating a high level of il-1
EP02712018A EP1363613A2 (fr) 2001-01-23 2002-01-23 Utilisation d'une rheine pour la preparation d'un medicament pour le traitement d'un taux eleve d'il-1.
MXPA03006596A MXPA03006596A (es) 2001-01-23 2002-01-23 Uso de una reina para preparacion de un medicamento para el tratamiento de un nivel elevado de il-1.
IL15695702A IL156957A0 (en) 2001-01-23 2002-01-23 Use of rhein for preparing a medicine for treating a high level of il-1
CA002434052A CA2434052A1 (fr) 2001-01-23 2002-01-23 Utilisation d'une rheine pour la preparation d'un medicament pour le traitement d'un taux eleve d'il-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/768,816 2001-01-23
US09/768,816 US20020128317A1 (en) 2001-01-23 2001-01-23 Treatment of pathological conditions characterized by an increased IL-1 level

Publications (3)

Publication Number Publication Date
WO2002058681A2 WO2002058681A2 (fr) 2002-08-01
WO2002058681A3 WO2002058681A3 (fr) 2002-12-19
WO2002058681A8 true WO2002058681A8 (fr) 2003-03-06

Family

ID=25083563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/000271 WO2002058681A2 (fr) 2001-01-23 2002-01-23 Utilisation d'une rhéine pour la préparation d'un médicament pour le traitement d'un taux élevé d'il-1.

Country Status (7)

Country Link
US (1) US20020128317A1 (fr)
EP (1) EP1363613A2 (fr)
AU (1) AU2002231927A1 (fr)
CA (1) CA2434052A1 (fr)
IL (1) IL156957A0 (fr)
MX (1) MXPA03006596A (fr)
WO (1) WO2002058681A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797727B2 (en) * 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
CN1314361C (zh) * 2003-04-02 2007-05-09 李安虎 一种关节保健饮品或食品及其制备方法
MXPA04009698A (es) * 2004-10-04 2006-04-05 Maria Elena Garcia Armenta Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
FR2920991A1 (fr) * 2007-09-14 2009-03-20 Wockhardt Ltd Composition a base de diacerheine pour le traitement de l'arthrose
WO2009034409A2 (fr) * 2007-09-14 2009-03-19 Wockhardt Research Centre Compositions pharmaceutiques de rheine ou de diacereine
EP2060562A1 (fr) * 2007-11-16 2009-05-20 Laboratoire Medidom S.A. Dérivés de sulfonate de dioxoanthracène
EP2280697A1 (fr) * 2008-04-30 2011-02-09 Wockhardt Research Centre Compositions liquides orales de rhéine ou de diacéréine
MX2018002049A (es) * 2015-08-17 2018-06-15 Twi Biotechnology Inc Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3.
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN110177547B (zh) * 2017-01-18 2022-09-27 台睿生物科技股份有限公司 用于治疗炎症性肠病和肠结肠炎的组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) * 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
GB9417102D0 (en) * 1994-08-24 1994-10-12 Lilly Industries Ltd Pharmaceutical compounds
NL1003503C2 (nl) * 1996-07-04 1998-01-07 Negma Steba International Dev Farmaceutische samenstelling voor orale toediening.
IT1283771B1 (it) * 1996-07-31 1998-04-30 Medidom Lab Procedimento per la preparazione di derivati della reina
IT1283772B1 (it) * 1996-07-31 1998-04-30 Medidom Lab Procedimento per la preparazione di reina e diacereina
JP4049406B2 (ja) * 1996-10-15 2008-02-20 正規 小菅 津液改善剤及びそれを含有する経口投与用組成物
JP4018764B2 (ja) * 1996-10-18 2007-12-05 正規 小菅 津液改善用皮膚外用剤
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
AR026801A1 (es) * 2000-01-12 2003-02-26 Medidom Lab Sustancias para uso en el tratamiento de la psoriasis

Also Published As

Publication number Publication date
WO2002058681A3 (fr) 2002-12-19
AU2002231927A1 (en) 2002-08-06
CA2434052A1 (fr) 2002-08-01
EP1363613A2 (fr) 2003-11-26
IL156957A0 (en) 2004-02-08
MXPA03006596A (es) 2004-05-05
WO2002058681A2 (fr) 2002-08-01
US20020128317A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
GB0128108D0 (en) Therapeutic use
WO2002058681A3 (fr) Utilisation d'une rhéine pour la préparation d'un médicament pour le traitement d'un taux élevé d'il-1.
HK1096859A1 (en) Methods for treating interleukin-6 related diseases
EP1600169A3 (fr) Dérivé de pyrrolidine acetamide, seul ou en combinaison, pour le traitement des maladies du système nerveux central
HUP0100867A2 (hu) Celecoxib tartalmú gyógyászati készítmények
PL367277A1 (en) Methods of making sustained release formulations of oxymorphone related applications
EP2298812A3 (fr) Remèdes pour maladies associées à l'arthrite chronique chez l'enfant
WO2003014309A3 (fr) Recepteurs de l'interleukine-1 dans le traitement de maladies
DE69905368D1 (en) Oxydiertes thymosin beta 4
AU2003239531A1 (en) Protein cages for the delivery of medical imaging and therapy
NO983543D0 (no) Preparat omfattende interleukin-1-inhibitor og polymer med regulert frigivelse
NZ530950A (en) 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
ZA200306171B (en) (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes.
WO2005018605A3 (fr) Nouvelle formulation
WO1999054460A3 (fr) Sequences d'acide nucleique provenant du tissu normal de la vessie
WO1999054447A3 (fr) Sequences d'acide nucleique provenant de tissus tumoraux de la vessie
Cavalli et al. Corrigendum: Anakinra therapy for non-cancer inflammatory diseases
SE9902597D0 (sv) New use
HK1073779A1 (en) The use of darifenacin and the salt thereof
AU2002322263A1 (en) Eglin c based drugs for treatment of disease
ATE254595T1 (de) 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten
WO1996041607A3 (fr) Compositions parmaceutiques comprenant de la restrictine p/activine a, et leur utilisation en qualite d'antagonistes de il-6 et/ou il-11
SE9904424D0 (sv) Use of interleukin-6 in combination with leptin in treatment of obesity
AU2002224253A1 (en) Medicine based on diethylaminoethanol derivatives and its use for the prevention and treatment of inflammatory and degenerative diseases
HUP0202416A2 (hu) Új kombinációs gyógyszerkészítmény és ennek alkalmazása kardiovaszkuláris rendellenességek kezelésében

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR CA CN CZ DZ HU ID IL IN JP KR LT LV MA MX NO NZ PL RO RU SG SI SK TR US VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BR CA CN CZ DZ HU ID IL IN JP KR LT LV MA MX NO NZ PL RO RU SG SI SK TR US VN ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

AK Designated states

Kind code of ref document: C1

Designated state(s): AU BG BR CA CN CZ DZ HU ID IL IN JP KR LT LV MA MX NO NZ PL RO RU SG SI SK TR US VN ZA

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE IN ENGLISH REPLACED BY CORRECT TITLE

WWE Wipo information: entry into national phase

Ref document number: 2002712018

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2434052

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 156957

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006596

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2002712018

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002712018

Country of ref document: EP